Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Afamelanotide cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Afamelanotide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

  1. Label: one implant every 2 months; the label does not state a maximum treatment duration 1.
  2. EMA overview: three implants per year recommended, maximum of four, before and during periods of high sunlight exposure 3.
  3. Pivotal trials: 180 days (CUV039, three implants) and 270 days (CUV029, five implants) 1.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Afamelanotide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Afamelanotide cycle length?
No cycle is defined. Afamelanotide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Afamelanotide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Afamelanotide dosing reference Full research page

References

  1. SCENESSE (afamelanotide) implant, for subcutaneous use. Prescribing information, CLINUVEL Inc. (SPL published May 13, 2026) DailyMed (FDA label). 2026
  2. Drugs@FDA application record for SCENESSE (afamelanotide), NDA 210797, original approval 8 October 2019 openFDA / Drugs@FDA. 2026
  3. Scenesse (afamelanotide): EPAR, medicine overview (authorised 22 December 2014 under exceptional circumstances) European Medicines Agency. 2026
  4. Afamelanotide for Erythropoietic Protoporphyria N Engl J Med. 2015
  5. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial JAMA Dermatol. 2015
  6. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders Clin Pharmacokinet. 2017
  7. Evaluation of the immunogenicity of the synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analogue afamelanotide ([Nle4-D-Phe7]-alpha-MSH, Scenesse) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-alpha-MSH antibodies Skin Pharmacol Physiol. 2015
  8. PubChem compound record for afamelanotide (CID 16197727; CAS 75921-69-6) PubChem. 2026
  9. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026